Clinical Trials Logo

Acute Disease clinical trials

View clinical trials related to Acute Disease.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT01956630 Active, not recruiting - Acute Leukemia Clinical Trials

Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT

Start date: September 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Allogeneic hematopoietic cell transplantation(Allo-HSCT) is currently an effective treatment for Acute leukemia (AL). Relapse after transplantation, being a main obstacle for patient survival, is so far treated by second transplantation and donor leukocyte infusion (DLI), which seems to have high risk and low survival. Need for a new medication on relapse is urgent. The immunotherapy using Dendritic cells (DCs) combined with cytokine induced killer (CIK) cells holds promise for the adjuvant treatment of AL to eradicate or control residual disease. This randomized study was conducted to evaluate the feasibility and effective of genetically modified DCs combining to CIK immunotherapy in relapse AL after allo-HSCT.

NCT ID: NCT00048958 Active, not recruiting - Multiple Myeloma Clinical Trials

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

Start date: June 1984
Phase:
Study type: Observational

Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.